90% MIBC patients with negative circulating DNA test post-surgery using Natera's Signatera test did not relapse in Phase III IMvigor011 trial.
Natera announces positive surveillance analysis from Phase III IMvigor011 trial in muscle-invasive bladder cancer, showing that 90% of MIBC patients with a negative circulating DNA test following surgery did not relapse. The company's Signatera test, a personalized molecular residual disease test, was used in the trial. This could lead to more targeted treatments and less unnecessary treatment for patients.
April 04, 2024
7 Articles